What's Happening?
ISOThrive Inc. has reported positive results from a Phase 2 clinical trial for its drug MHS-1031, aimed at treating patients with Non-Erosive Reflux Disease (NERD) who do not respond adequately to proton pump inhibitors (PPIs). The study, presented at Digestive
Disease Week 2026, demonstrated statistically significant reductions in heartburn incidence, severity, and regurgitation. NERD affects approximately 70% of the GERD population, which is about 45 million adults in the U.S. Despite existing treatments like PPIs and potassium-competitive acid blockers (PCABs), many patients continue to experience symptoms. MHS-1031, a patented oligosaccharide, works by modulating the esophageal microbiome to reduce inflammatory signaling, offering a novel approach beyond traditional acid suppression therapies.
Why It's Important?
The development of MHS-1031 is significant as it addresses a large unmet need in the treatment of NERD, a condition that affects a substantial portion of the GERD population. Current therapies often fail to fully alleviate symptoms, leaving many patients with persistent discomfort. By targeting the microbiome rather than just suppressing acid, MHS-1031 could provide a more comprehensive treatment option. This advancement could lead to improved quality of life for millions of Americans suffering from NERD and potentially reduce healthcare costs associated with ongoing symptom management.
What's Next?
ISOThrive plans to continue its clinical development of MHS-1031, with further studies likely needed to confirm these findings and potentially lead to FDA approval. The company is working with leading investigators from institutions like Vanderbilt University and the University of Virginia. If successful, MHS-1031 could become a new standard in treating NERD, offering relief to patients who have not found success with existing medications.
